Exenatide Plus Dapagliflozin Combination: Better Metabolic Outcomes Than Either Alone | Research

The takeaway

Combining exenatide (GLP-1 agonist) with dapagliflozin (SGLT2 inhibitor) provided superior metabolic management compared to either drug alone in type 2 diabetes patients.

Combination wins
GLP-1 agonist + SGLT2 inhibitor combination provides superior metabolic outcomes through complementary mechanisms

What the researchers found

Exenatide + dapagliflozin combination achieved superior HbA1c reduction, weight loss, and metabolic outcomes versus either drug alone through complementary mechanisms.

Why it matters

Combining drugs with different mechanisms should produce additive benefits — and this study confirms it. GLP-1 + SGLT2 combinations could become standard for patients needing aggressive metabolic management.

The numbers in context

Mean differences with 95% confidence intervals were calculated. Four databases were searched for relevant RCTs.

How the study worked

Clinical study comparing exenatide + dapagliflozin combination vs monotherapy. Assessed HbA1c, body weight, metabolic parameters.

Who was studied

Type 2 diabetes patients across randomized controlled trials

What this study cannot tell us

Study specifics vary. Cost of dual therapy is higher. Some patients may experience more side effects with combination.

How to read the evidence

Moderate evidence: clinical comparison showing combination superiority over monotherapy.

When this study was published

Published in 2025. Supports the trend toward combination metabolic therapy.

The bigger picture

GLP-1 + SGLT2 combinations address diabetes from two angles simultaneously: GLP-1 improves insulin function and reduces appetite, while SGLT2 eliminates excess glucose through the kidneys. This dual approach also provides cardiovascular and kidney protection from both drug classes.

Questions still open

Is GLP-1 + SGLT2 combination better than GLP-1 + metformin for initial therapy?
Do cardiovascular and kidney benefits add synergistically with combination?
Should all T2D patients receive combination GLP-1 + SGLT2 therapy?

Common questions

Why combine two diabetes drugs?

Exenatide and dapagliflozin work through completely different mechanisms — one enhances insulin and reduces appetite, the other removes excess glucose through the kidneys. Together they achieve better blood sugar control and more weight loss than either alone.

Is combination therapy worth the extra cost?

For many patients, yes. Better metabolic control prevents expensive complications (heart disease, kidney failure, amputations). The combination also provides dual cardiovascular and kidney protection. Discuss cost-benefit with your healthcare provider.

Read the original research

Efficacy of the Combination of Exenatide and Dapagliflozin in the Management of Diabetes and Weight Control: A Network Meta-Analysis.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

View on PubMed ↗Publisher’s paper ↗

Citation

Abuali, Ahmed; Abdelhamid, Abdelrahman; Elsekaily, Ahmed Elsayed; Seoudy, Mohamed; Elnaghy, Mohamed; Ragab, Youssef; Elkholy, Mohammed; Sharara, Muhannad; Mahrous, Mostafa; Alnasser, Yusra; Ragab, Khaled Mohamed; Abdelhadi, Naser. (2025). Efficacy of the Combination of Exenatide and Dapagliflozin in the Management of Diabetes and Weight Control: A Network Meta-Analysis.. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. https://doi.org/10.1055/a-2737-6110